Method for identifying compounds for inhibition of cancerous les

Details Method for identifying compounds for inhibition of cancerous les Method for identifying compounds for inhibition of cancerous les

1997-05-30

1999-01-12

Gitomer, Ralph

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving hydrolase

435184, C12Q 144

Patent

active

058586946

ABSTRACT:
This invention provides a method to identify compounds potentially useful for the treatment of neoplasia in mammals. The phosphodiesterase inhibitory activity of a compound is determined along with COX inhibitory activity. Growth inhibitory and apoptosis inducing effects on cultured tumor cells are also determined. Compounds that exhibit phosphodiesterase inhibiton, growth inhibition and apoptosis induction, but not substantial prostaglandin inhibitory activity, are desirable for the treatment of neoplasia.

REFERENCES:
patent: 4983514 (1991-01-01), Weithmann et al.
patent: 5389527 (1995-02-01), Beavo et al.
patent: 5393755 (1995-02-01), Neustadt et al.
patent: 5401774 (1995-03-01), Pamukcu et al.
patent: 5439895 (1995-08-01), Lee et al.
patent: 5498608 (1996-03-01), Johnson et al.
patent: 5521191 (1996-05-01), Greenwald
patent: 5570683 (1996-11-01), Zapol
patent: 5624808 (1997-04-01), Thompson et al.
patent: 5626838 (1997-05-01), Cavanaugh, Jr.
patent: 5637465 (1997-06-01), Trauth
patent: 5637486 (1997-06-01), Tomei
patent: 5643959 (1997-07-01), Pamukcu et al.
patent: 5652131 (1997-07-01), Beavo et al.
patent: 5702936 (1997-12-01), Beavo et al.
Boopathy, R. and A. S. Balasubramanian, "Purification and Characterization of Sheep Platelet Cyclo-oxygenase," Biochem. J. , vol. 239, pp. 371-377. (1986).
Brooker, G. et al., "Radioimmunoassay of Cyclic AMP and Cyclic GMP," Advances in Cyclic Nucleotide Research, Raven Press, New York, vol. 10, pp. 1-33. (1979).
Collins, S. J. et al., "Normal Functional Characteristics of Cultured Human Promyelocytic Leukemia Cells (HL-60) After Induction of Differentiation by Dimethylsulfoxide," The Journal of Experimental Medicine, vol. 149, pp. 969-974. (1979).
Duke, R. C. and J. J. Cohen, "Morphological and Biochemical Assays of Apoptosis," Current Protocols in Immunology, John Wiley & Sons, New York, eds. J.E. Coligan, et al., sections 3.17.1-3.17.16. (1992).
Fogh, J. and G. Trempe, "New Human Tumor Cell Lines," Human Tumor Cells In Vitro, Plenum Press, New York, pp. 115-141. (1975).
Kargman, S et al., "Translocation of HL-60 Cell 5-Lipoxygenase," J. Biol. Chem., vol. 266, No. 35, pp. 23745-23752. (1991).
Mehta, R. G. and R. C. Moon, "Effects of 12-0-tetradecanoylphorbol-13-acetate on Carcinogen-induced Mouse Mammary Lesions in Organ Culture," Cancer Research, vol. 46, pp. 5832-5835. (1986).
Mitchell, J. A. et al., "Selectivity of nonsteroidal antinflammatory drugs as inhibitors of constitutive and inducible cyclooxgenase," Proc. Natl. Acad. Sci. USA, vol. 90, pp. 11693-11697. (1994).
Piazza, G. A. et al., "Antineoplastic Drugs Sulindac Sulfide and Sulfone Inhibit Cell Growth by Inducing Apoptosis," Cancer Research, vol. 55, pp. 3110-3116. (1995).
Seibert, A. F. et al., "Reversal of Increased Microvascular Permeability Associated With Ischemia-reperfusion: Role of cAMP," J. Applied Physiol., pp. 389-395. (1992).
Skehan, P. et al., "New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening," J. Nat. Cancer Inst., vol. 82, No. 13, pp. 1107-1112. (1990).
Steiner, A. L. et al., "Radioimmunoassay for Cyclic Nucleotides," J. Biol. Chem., vol. 247, No. 4, pp. 1106-1113. (1972).
Thompson, H. J. et al., "Inhibition of Mammary Carcinogenesis in Rats by Sulfone Metabolite of Sulindac," J. Nat. Cancer Inst., vol. 87, No. 16, pp. 1259-1260. (1995).
Thompson, W. J. et al., "Assay of Cyclic Nucleotide Phosphodiesterase and Resolution of Multiple Molecular Forms of the Enzyme," Advances in Cyclic Nucleotide Research, Raven Press, New York, vol. 10, pp. 69-92. (1979).
Waddell, W. R. and R. W. Loughry, "Sulindac for Polyposis of the Colon," J. Surg. Oncol., vol. 24, pp. 83-87. (1983).
Tsou, K.C. et al.; Histochemical Journal, 6 (1974) pp. 327-337.
Tsou, K.C. et al.; Cancer Research 33: 2215 2217, (Oct. 1973).
Tsou, K.C. et al.; Cancer Research 50:191-196, (1982).
Tsou, K.C. et al,; Cancer Reseach 45:209-213, (1980).
Tsou, K.C. et al,; Journal of the National Cancer Institute, vol. 51, No. 6, (Dec. 1973).
Tsou, K.C. et al.; Oncology 37: 381-385 (1980).
Tsou, K.C. et al.; Journal of Clinical Hematology And Oncology., vol. 10, No. 1, (Jan. 1980).
Morley, Debra J. et al.; The Journal of Histochemistry and Cytochemistry, vol. 35, No. 1, pp. 75-82 (1987).
Cancer Research 58: 914-920 (Mar. 1, 1998) Sugita M.
Beavo, Joseph; Physiological Reviews, vol. 75, No. 4, (Oct. 1995).
Beltman et al.; Molecular Pharmacology, 47:330-339 (1995).
Essayan et al.; The Journal of Immunology, 153: 3408 (1994).
Beavo et al.; Molecular Pharmacology, 46:399-405 (1994).
Qiao et al.; Biochemical Pharmacology, vol. 55, pp. 53-64 (1998).
Japan. J. Pharmacol. 46, 373-378 (1988) Takagi K.
Tulshian et al.; Journal of Medicinal Chemistry vol. 36., No. 9; pp. 1210-1220 (1993).
Pfizer Inc.; BioCentry, The Bernstein Report on BioBusiness, p. A4 (Jul. 14, 1997).
Terrett, Nicholas et al.; Bioorganic & Medicinal Chemistry Letters, vol. 6, No. 15, pp. 1819-1824 (1996).
Silvola et al.; Agents and Actions, vol. 12.4 (1982).
Drees et al.; Cancer Research, 53:3058-3061, (Jul. 1, 1973).
Wilhelm et al.; Syntex Research, 8-Aryl Quinolines As Potent and Selective Type Iv Phosphodiesterase Inhibitors. No Date Avail.
Thompson, W. Joseph; Pharmac. Ther. vol. 51, pp. 13-33 (1991).
Yasumoto et al.; Biochemical Pharmacology, vol. 43, No. 10. pp. 2073-2081 (1992).
Villone et al.; vol. 8, pp. 1181-1188 (Nov. 1997).
Tortora et al.; Cancer Research 57:5107-5111 (Nov. 15, 1997).
Sandberg et al.; Biochemistry vol. 279, pp. 521-527 (1991).
Vintermyr et al.; Experimental Cell Research vol. 206. pp. 157-161 (1993).
McConkey et al.; The Journal of Immunology vol. 145 No. 4 pp. 1227-1230 (1990).
Dowd et al,; Molecular and Cellular Biology vol. 12, No. 8 pp. 3600-3608 (1992).
Botelho et al,; Methods in Enzymology, vol. 159 pp. 159-171 1988.
Kizaki et al.; The Journal of Biological Chemistry vol. 265, No. 9 pp. 5280-5284 (Mar. 25, 1990).
Kemp et al.; Cancer Research 35:2440-2445 (Sep. 1975).
Willey et al.l; Journal of Cellular Physiology 124:207-212 (1985).
Chastre et al.; FEBS Letters vol. 188, No. 2 pp. 197-204 (Sep. 1985).
Busse et al.; Oncology 48:196-201 (1991).
Tortora et al.; Clinical Cancer Research vol. 1, pp. 46-56 (Jan. 1995).
Lando et al.; Cancer Research 50:722-727 (Feb. 1, 1990).
Quedraogo et al.; Br. J. Pharmacol 111. pp. 625-631 (1994).
Just et al.; Biochemical Pharmacology vol. 42, No. 2. pp. 285-294 (1991).
Gruol et al.; Molecular Endocrinology vol. 7, No. 1. pp. 104-113 (1993).
Ojeda et al.; Induction of Apoptosis in Thymocytes: New Evidence for an Interaction of PKC and PKA Pathways 1995.
Lanotte et al.; Journal of Cellular Physiology 146:73-80 (1991).
Krett et al.; Clinical Cancer Research vol. 3. pp. 1781-1787 (Oct. 1997).
Nesbitt et al.; The Journal of Biological Chemistry vol. 251, No. 8. pp. 2344-2352 (Apr. 25, 1976).
Gennari et al.; Journal of Clinical Pathology vol. 31 pp. 735-741 (1978).
Orbo et al.; Anticancer Research 75: pp. 1905-1910 (1995).
Orbo et al.; Gynecologic Oncology vol. 52. pp. 320-325 (1994).
Duttagupta et al.; Cancer Research vol. 42. pp. 2938-2942 (Jul. 1982).
Barsony, Julie; The Second International Forum on Calcified Tissue and Bone Metabolism pp. 18-21 (1993).
Wedner et al.; The Journal of Immunology vol. 115, No. 6. pp. 1682-1687 (Dec. 1975).
Coffey et al.; The Journal of Immunology vol. 119, No. 4. pp. 1387-1394 (Oct. 1977).
Pilz et al.; Research Communication vol. 9. pp. 552-558 (Apr. 1995).
Tsang et al.; Science vol. 272. (May 17, 1996).
Appel, Richard G.; The American Physiological Society. pp. E312-318 (1990).
Keilbach et al.; FEBS EJB 92 0649. pp. 467-473 (May 12, 1992).
Hadden et al.; Proc. Nat. Acad. Sci. USA vol. 69, No. 10, pp. 3024-3027 (Oct. 1972).
Orbo et al.; International Journal Cancer; vol. 55. pp. 957-962 (1993).
Tien et al.; vol. 269, No. 1. pp. 51-54 (1994).
Tang et al.; European Journal of Pharmacology; Molecular Pharmacology Section 268. pp. 105-114 1994).
Remme et al.; J. Cardiovasc. Pharmacol. vol. 24, No. 5 (Nov. 1994) AB only.
Weiss et al.; Clinical Exp. Pharmacol.Physiol. vol. 21, No. 8 (Aug. 1994) AB only.
Lee et al.; J. Pharmacol.Exp.Ther. vol. 270,

Affiliated with

Also associated with

Rating

Method for identifying compounds for inhibition of cancerous les does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for identifying compounds for inhibition of cancerous les, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for identifying compounds for inhibition of cancerous les will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1514194